93 POSTER Phase I study of daily oral AZD2171, an inhibitor of the vascular endothelial growth factor receptors (VEGFR), in combination with oxaliplatin and Infusional 5-Fu (mFOLFOX6) in patients with advanced colorectal cancer (CRC): a study of the National Cancer Institute of Canada Clinical Trials Group

✍ Scribed by E. Chen; D. Jonker; M. Maclean; J. Wells; S. Mathews; J. Robertson; L. Seymour

• Book ID: 118623722
• Publisher: Elsevier Science
• Year: 2006
• Tongue: English
• Weight: 57 KB
• Volume: 4
• Category: Article
• ISSN: 1359-6349
• DOI: 10.1016/s1359-6349(06)70099-4